Microsatellite alterations and cell-free dna analysis: Could they increase the cytology sensitivity in the diagnosis of malignant pleural effusion?

Rejuvenation Research

Volumn 15, Issue 3, 2012, Pages 265-273

  Carpagnano, Giovanna E ^a   Costantino, Elio ^a   Palladino, Grazia P ^a   Lacedonia, Donato ^a   Martinelli, Domenico ^a   Orlando, Silvio ^b   Foschino Barbaro, Maria P ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b University of Foggia and Apulia Regional Epidemiological Observatory ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; BREAST CARCINOMA; CANCER STAGING; CELL FREE SYSTEM; COLON CARCINOMA; CYTOLOGY; DNA DETERMINATION; FEMALE; GENETIC MARKER; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; OVARY CARCINOMA; PLEURA EFFUSION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW;

ANTHROPOMETRY; CELL-FREE SYSTEM; CYTODIAGNOSIS; DNA, NEOPLASM; EXHALATION; FEMALE; HETEROZYGOTE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED; MUTATION; PLEURAL EFFUSION, MALIGNANT; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 84863453033     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2011.1260     Document Type: Review

References (36)

1. Chan MH, Chow KM, Chan AT, Leung CB, Chan LY, Chow KC, LAm CW, Lo YM. Quantitative analysis of pleural fluid cell-free DNA as a tool for the classification of pleural effusions. Clin Chem 2003;49:740-745. (Pubitemid 36513252)
2. Light RW. Malignant pleural effusions. In: Light RW (ed). Pleural Diseases, 3rd ed. Williams & Wilkins, Baltimore, 1995, pp. 94-116.
3. Miedouge M, Rouzaud P, Salama G, Pujazon. MC, Vincent C, Mauduyt MA, Reyre J, Carles P, Serre G. Evaluation of seven tumors markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer 1999;81:1059-1065. (Pubitemid 29516152)
4. Benlloch S, Galbis-Caravajal JM, Mart́n C, Sanchez-Paya J, Rodriguez-Paniagua JM, Romero S, Mafe JJ, Massuti B. Potential diagnostic value of methylation profile in pleural fluid and serum from cancer patients with pleural effusion. Cancer 2006;107:1859-1865. (Pubitemid 44582956)
5. Economidou F, Tzortzaki EG, Schiza S, Antoniou KM, Neofytou E, Zervou M, Lambiri I, Siafakas NM. Microsatellite DNA analysis does not distinguish malignant from benign pleural effusions. Oncol Rep 2007;18:1507-1512.
6. Bruggers C, White K, Zhou H, Chen Z. Extracranial relapse of an anaplastic oligodendroglioma in an adolescent: Case report and review of the literature. J Pediatr Hematol Oncol 2007;29:319-322. (Pubitemid 46707513)
7. Tug E, Tug T, Elyas H, Coskunsel M, Emri S. Tumor suppressor gene alterations in patients with malignant mesothelioma due to environmental asbestos exposure in Turkey. J Carcinog 2006;22;5:23.
8. Simon F, Johnen G, Krismann M, Muller KM. Chromosomal alterations in early stages of malignant mesotheliomas. Virchow's Arch 2005;447:762-767. (Pubitemid 41571193)
9. Lee JH, Hong YS, Ryu JS, Chang JH. p53 and FHIT mutations and microsatellite alterations in malignancy-associated pleural effusion. Lung Cancer 2004;44:33-42. (Pubitemid 38317260)
10. Merz H, Lange K, Gaiser T, Muller A, Kapp U, Bittner C, Harder S, Siebert R, Bentz M, Binder T, Diehl V, Feller AC. Characterization of a novel human anaplastic large cell lymphoma cell line tumorigenic in SCID mice. Leuk Lymphoma 2002;43:165-172. (Pubitemid 34223986)
11. Liu E, Dollbaum C, Scott G, Rochlitz C, Benz C, Smith HS. Molecular lesions involved in the progression of a human breast cancer. Oncogene 1988;3:323-327.
12. Nakamoto M, Teramoto H, Matsumoto S, Igishi T, Shimizu E. K-ras and rho A mutations in malignant pleural effusion. Int J Oncol 2001;19:971-976.
13. Huang MJ, Lim KH, Tzen CY, Hsu HS, Yen Y, Huang BS. EGFR mutations in malignant pleural effusion of non-small cell lung cancer: A case report. Lung Cancer 2005;49:413-415. (Pubitemid 41139155)
14. Kimura H, Fujiwara Y, Sone T, Kunitoh H, Tamura T, Kasahara K, Nishio K. EGFR mutation status in tumourderived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006; 95:1390-1395. (Pubitemid 44760091)
15. Carrión-Valero F, Perpiñ á-Tordera M, Sanchis-Aldás J. Screening of malignant pleural effusion by discriminant analysis. Int J Tuberc Lung Dis 2003;7:892-898. (Pubitemid 37158430)
16. Carpagnano GE, Palladino GP, Gramiccioni C, Foschino Barbaro MP, Martinelli D. Exhaled ERCC-1 and ERCC-2 microsatellite alterations in NSCLC patients. Lung Cancer 2010; 68:305-307.
17. Carpagnano GE, Spanevello A, Palladino GP, Gramiccioni C, Ruggieri C, Carpagnano F, Foschino Barbaro MP. Cigarette smoke and increased COX-2 and survivin levels in exhaled breath condensate of lung cancer patients: How hot is the link? Lung Cancer 2010;67:108-113.
18. Carpagnano GE, Spanevello A, Carpagnano F, Palladino GP, Prato R, Martinelli D, Digioia G, Foschino-Barbaro MP. Prognostic value of exhaled microsatellite alterations at 3p in NSCLC patients. Lung Cancer 2009;64:334-340.
19. Paradiso A, Tommasi S, Pinto R, Carpagnano GE, Foschino-Barbaro MP. Exhaled breath condensate is not suitable to detect EGFR somatic mutations. Eur Respir J 2008;32:1126-1127.
20. Carpagnano GE, Foschino-Barbaro MP, Spanevello A, Resta O, Carpagnano E, Mule G, Pinto R, Tommasi S, Paradiso A. 3p microsatellite signature in exhaled breath condensate and tumor tissue of patients with lung cancer. Am J Respir Crit Care Med 2008;177:337-341. (Pubitemid 351198378)
21. Carpagnano GE, Foschino-Barbaro MP, Mulé G, Resta O, Tommasi S, Mangia A, Carpagnano F, Stea G, Susca A, Di Gioia G, De Lena M, Paradiso A. 3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer. Am J Respir Crit Care Med 172(6):738-44, 2005. (Pubitemid 41324229)
22. Ko JC, Su YJ, Lin ST, Jhan JY, Ciou SC, Cheng CM, Chiu YF, Kuo YH, Tsai MS, Lin YW. Emodin enhances cisplatininduced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer 2009;69:155-164.
23. Light RW, McGregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: The diagnostic separation of transudates and exudates. Ann Intern Med 1972;77:507-513.
24. American Joint Committee on Cancer Staging Handbook, 5th ed. Lipincott-Raven, Philadelphia, 1998, pp 117-129.
25. Chen H, Brahmer J. Management of malignant pleural effusion. Curr Oncol Rep 2008;10:287-293.
26. Granja Nde M, Ricardo SA, Longatto Filho A, Alves VA, Bedrossian CW, Wiley EL, Schmitt FC. Potential use of loss of heterozygosity in pleural effusions of breast cancer metastases using the microsatellite marker of the 16q22.1 region of the CDH1 gene. Anal Quant Cytol Histol 2005;27: 61-66. (Pubitemid 40563154)
27. Lo YMD, Chan LYS, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res 1999;59:1188-1191. (Pubitemid 29136244)
28. Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananev V, Bazin I, Garin A, Narimanov M, Knysh V, Melkonyan H, Umansky S, Lichtenstein A. Genetic analysis of DNA excreted in urine: A new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem 2000;46:1078-1084. (Pubitemid 30643308)
29. Sarkar S, Bhattacharya G, Bandyopadhyay S, Bhattacharjee S, Banerjee D. Identification of orcinol reactive substance in pleural fluid cell lysate-a new parameter for classification of pleural effusion. Clin Chim Acta 2010;411:671-674.
30. Loddenkemper R, Grosser H, Gabler A, Mai J, Preussler H, Brandt HJ. Prospective evaluation of biopsy methods in the diagnosis of melignant pleural effusions: Intrapatient comparison between pleural fluid cytology, blind needle biopsy and thoracoscopy. Am Rev Respir Dis 1983;127(Suppl 4): 114.
31. Antony VB, Loddenkemper R, Astoul PH, Boutin C, Goldstraw P, Hott J, Todriguez Panadero F, Sahn SA. Manage-ment of malignant pleural effusions. Am J Respir Crit Care Med 2000;162:1987-2001.
32. Schuster N, Krieglstein K. Mechanisms of TGF-b-mediated apoptosis. Cell Tissue Res 2002;307:1-14.
33. Karatzanis AD, Samara KD, Tzortzaki E, Zervou M, Helidonis ES, Velegrakis GA, Siafakas N. Microsatellite DNA instability in nasal cytology of COPD patients. Oncol Rep 2007;17:661-665.
34. Marsit CJ, Wiencke JK, Nelson HH, Kim DH, Hinds PW, Aldape K, Kelsey KT. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. Cancer Genet Cytogenet 2005; 162:115-121. (Pubitemid 41423467)
35. Sanchez-Cespedes M, Decker PA, Doffek KM, Esteller M, Westra WH, Alawi EA, Herman JG, Demeure MJ, Sidransky D, Ahrendt SA. Increased loss of chromosome 9p21 but not p16 inactivation in primary non-small cell lung cancer from smokers. Cancer Res 2001;61:2092-2096. (Pubitemid 32692032)
36. Hirao T, Nelson HH, Ashok TD, Wain JC, Mark EJ, Christiani DC, Wiencke JK, Kelsey KT. Tobacco smoke-induced DNA damage and an early age of smoking initiation induce chromosome loss at 3p21 in lung cancer. Cancer Res. 2001; 61:612-615. (Pubitemid 32128623)